Reasons for discontinuation of GLP1 receptor agonists: data from a real-world cross-sectional survey of physicians and their patients with type 2 diabetes

References

• World Health Organization Global Report on Diabetes 2016 Geneva WHO 2016
   Google Scholar
• American Diabetes Association Approaches to glycemic treatment Diabetes Care 2016 39 Suppl 1 S52 S59 26696682
   PubMed Web of Science ®Google Scholar
• Davidson JA Incretin-based therapies: focus on effects beyond glycemic control alone Diabetes Ther 2013 4 2 221 238 24057947
   PubMed Web of Science ®Google Scholar
• Fabunmi R Nielsen LL Quimbo R Patient characteristics, drug adherence patterns, and hypoglycemia costs for patients with type 2 diabetes mellitus newly initiated on exenatide or insulin glargine Curr Med Res Opin 2009 25 3 777 786 19203299
   PubMed Web of Science ®Google Scholar
• Divino V DeKoven M Hallinan S Glucagon-like peptide-1 receptor agonist treatment patterns among type 2 diabetes patients in six European countries Diabetes Ther 2014 5 2 499 520 25366334
   PubMed Web of Science ®Google Scholar
• Johnston SS Nguyen H Felber E Retrospective study of adherence to glucagon-like peptide-1 receptor agonist therapy in patients with type 2 diabetes mellitus in the United States Adv Ther 2014 31 11 1119 1133 25408484
   PubMed Web of Science ®Google Scholar
• Anderson P Benford M Harris N Karavali M Piercy J Real-world physician and patient behaviour across countries: disease-specific programmes – a means to understand Curr Med Res Opin 2008 24 11 3063 3072 18826746
   PubMed Web of Science ®Google Scholar
• Wood R Paoli CJ Hays RD Taylor-Stokes G Piercy J Gitlin M Evaluation of the consumer assessment of healthcare providers and systems in-center hemodialysis survey Clin J Am Soc Nephrol 2014 9 6 1099 1108 24832092
   PubMed Web of Science ®Google Scholar
• Rodriguez MR Small M Fermer S Bailey J Wood R Fink-Wagner AH Real world burden of COPD: employed vs not in paid employment patients J Health Prod 2013 7 1 29 44
   Google Scholar
• Babineaux SM Curtis B Holbrook T Milligan G Piercy J Evidence for validity of a national physician and patient-reported, cross-sectional survey in China and UK: the Disease Specific Programme BMJ Open 2016 6 8 e010352
   PubMed Web of Science ®Google Scholar
• Higgins V Piercy J Roughley A Trends in medication use in patients with type 2 diabetes mellitus: a long-term view of real-world treatment between 2000 and 2015 Diabetes Metab Syndr Obes 2016 9 371 380 27843332
   PubMed Web of Science ®Google Scholar
• Atun RA Lennox-Chhugani N Drobniewski F Samyshkin YA Coker RJ A framework and toolkit for capturing the communicable disease programmes within health systems: tuberculosis control as an illustrative example Eur J Public Health 2004 14 3 267 273 15369032
   PubMed Web of Science ®Google Scholar
• European Pharmaceutical Market Research Association Code of Conduct Available from: http://www.ephmra.org/code-of-conduct/157/ Accessed January 18, 2017
   Google Scholar
• Department of Health and Human Services Summary of the HIPAA privacy rule 2016 Available from: https://www.hhs.gov/hipaa/for-professionals/privacy/laws-regulations/index.html Accessed January 18, 2017
   Google Scholar
• Market Research Society The Data Protection Act 1998 and market research: guidance for MRS members 2003 Available from: https://www.mrs.org.uk/pdf/The%20Data%20Protection%20Act%201998%20and%20Market%20Research.pdf Accessed January 18, 2017
   Google Scholar
• Donnelly LA Morris AD Pearson ER Adherence in patients transferred from immediate release metformin to a sustained release formulation: a population-based study Diabetes Obes Metab 2009 11 4 338 342 19267712
   PubMed Web of Science ®Google Scholar
• Florez H Luo J Castillo-Florez S Impact of metformin-induced gastrointestinal symptoms on quality of life and adherence in patients with type 2 diabetes Postgrad Med 2010 122 2 112 120
   PubMed Web of Science ®Google Scholar
• Sanyal D Majumdar A Low dose liraglutide in Indian patients with type 2 diabetes in the real world setting Indian J Endocrinol Metab 2013 17 Suppl 1 S301 S303 24251194
   PubMedGoogle Scholar
• Seufert J Gallwitz B The extra-pancreatic effects of GLP-1 receptor agonists: a focus on the cardiovascular, gastrointestinal and central nervous systems Diabetes Obes Metab 2014 16 8 673 688 24373150
   PubMed Web of Science ®Google Scholar
• Trujillo JM Nuffer W Ellis SL GLP-1 receptor agonists: a review of head-to-head clinical studies Ther Adv Endocrinol Metab 2015 6 1 19 28 25678953
   PubMed Web of Science ®Google Scholar
• Porcellati F Lucidi P Bolli GB Fanelli CG GLP-1 RAs as compared to prandial insulin after failure of basal insulin in type 2 diabetes: lessons from the 4B and Get-Goal DUO 2 trials Diabetes Metab 2015 41 6 Suppl 1 6S16 6S20 26774015
   PubMedGoogle Scholar
• Elliott L Fidler C Ditchfield A Stissing T Hypoglycemia event rates: a comparison between real-world data and randomized controlled trial populations in insulin-treated diabetes Diabetes Ther 2016 7 1 45 60 26886441
   PubMed Web of Science ®Google Scholar
• Cefalu WT Buse JB Del Prato S Beyond metformin: safety considerations in the decision-making process for selecting a second medication for type 2 diabetes management – reflections from a diabetes care editors’ expert forum Diabetes Care 2014 37 9 2647 2659 25147257
   PubMed Web of Science ®Google Scholar
• Prasad-Reddy L Isaacs D A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond Drugs Context 2015 4 212283 26213556
   PubMedGoogle Scholar
• Vilsbøll T Christensen M Junker AE Knop FK Gluud LL Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials BMJ 2012 344 d7771 22236411
   PubMed Web of Science ®Google Scholar
• Saunders C Byrne CD Guthrie B External validity of randomized controlled trials of glycaemic control and vascular disease: how representative are participants? Diabet Med 2013 30 3 300 308 23075287
   PubMed Web of Science ®Google Scholar